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Abstract 
 
The cation independent mannose 6-phosphate/insulin-like growth factor 2 
(M6P/IGF2R) is a multifunctional receptor. It is involved in a variety of cellular 
processes which become disregulated in cancer. Its tumor suppressor role was recognized 
a long time ago. However, due to its multifunctionality, it is not easy to understand the 
extent of its relevance to normal cellular physiology. Accordingly, it is even more 
difficult understanding its role in carcinogenesis. This review presents critical and 
focused highlights of data relating to M6P/IGF2R, obtained during more than 25 years of 
cancer research. 
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1. Introduction  
The cation independent mannose-6-phosphate/insulin-like growth factor 2 
(M6P/IGF2R) is a multiple ligand - binding cell surface receptor, ubiquitously expressed 
in human tissues. Its truncated soluble form is present in the circulatory system 
(~0.7 g/mL) [1]. The human gene for M6P/IGF2R, considered to be a tumor suppressor, 
is located at 6q26, spread over approximately 137 kb of genomic DNA. It consists of 48 
exons which make an open reading frame encoding a protein of 2491 amino acids (AA) 
[2]. The first 40 AAs represent a cleavable residue segment [3]. For this reason, some 
discrepancies relating to numbering the amino acids arose in the literature. For most 
researchers, methionine is the first AA that needs to be counted (M1). Other researchers 
count glutamine (Q41) as the first amino acid of the IGF2R protein sequence [3, 4]. This 
creates a certain amount of confusion, especially when it comes to the topographic 
localization of point mutations. For that reason, we have based this review on the 
comprehensive genomic and mRNA sequence of M6P/IGF2R, which are available in the 
GeneBank under accession numbers NG_011785 and NM_000876, respectively. In this 
review, we consider methionine, coded by nucleotides ATG and positioned at cDNA 
149-151, the first amino acid in the M6P/IGF2R protein structure and we count the rest of 
amino acids accordingly. The structure of the protein, related to the M6P/IGF2R coding 
region, is shown in Figure 1. The protein repeats are shown to be consistent with the 
updated data on IGF2R structure, UniProtKB/Swiss-Prot, Accesion P11717. This 
structure differs slightly from the data, first published in1998, on IGF2R repeats borders, 
starting with repeat 13 [3]. 
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2. M6P/IGF2R – Multifunctional receptor 
 
The major part of the protein consists of a large extracellular domain (2264 AAs), 
a very short transmebrane domain (23AAs, 2305-2327), and a cytoplasmic domain that is 
164 amino acids long (AAs 2328-2491), constituting the C-terminus [4]. The spacial 
organization of the extracellular domain (AAs 41-2304) creates 15 homologous 
extracellular repeats (134-167 AAs long) which represent 15 homologous structural units 
[3]. They display significant similarity in amino acid sequence and disulphide distribution 
(16-38%). This kind of structure already indicates multifunctional binding properties and, 
consequentially, multiple functioning. This includes the physiological processes of 
lysosomal enzyme trafficking, endocytosis and lysosomal degradation of extracellular 
ligands and regulation of apoptotic and mitogenic effects [5]. The significance of 
M6P/IGF2R can be best understood through the structure and roles of its ligands. Hence, 
it is not surprising that a majority of the research relating to M6P/IGF2R focuses on this 
part of its biological significance.  
The M6P/IGF2R ligands’ list is quite long and is divided into two general classes: 
those containing mannose-6-phosphate (M-6-P) and those that are mannose-6-phosphate 
free.  
The targeting of newly synthesized hydrolases to the lysosome has been a well- 
recognized function of M6P/IGF2R. This action is possible because it „recognizes“ the 
M-6-P residue on N-linked oligosaccharides which allows the process of hydrolase 
sorting. The receptor initially binds hydrolase in the Golgi. The release of hydrolases 
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from the receptor happens when acidity increases. This event takes place in the pre-
lysosomal compartment. The next step is recycling of the receptor into the Golgi 
apparatus to repeat the process, or moving the receptor to the plasma membrane [6]. 
Some M-6-P bearing ligands, with well-known relevance to cancer, are leukemia 
inhibitory factor, proliferin and cathepsin D - a strong promoter of cancer cell 
proliferation and invasion which is included in lysosome biogenesis [7-9]. There are also 
some multi-protein complexes containing the latent TGF-  which binds to the membrane 
M6P/IGF2R, to be activated extracellulary [10].  
Among M6P/IGF2R ligands without M-6-P, the most relevant to cancer may be 
insulin-like growth factor 2 [11], urokinase-type plasminogen activator receptor (uPAR) 
[12], retinoic acid [13], serglycin [14] and heparanase [15]. Recently, CREG (cellular 
repressor of E1A-stimulated genes 1) was also shown to be a M6P/IGF2R ligand. The 
consequence of their binding is cell growth suppression, probably through M6P/IGF2R-
mediated CREG subcellular distribution [16]. 
Retinoic acid (RA) (with a still unknown binding site) and non-glycosylated 
peptide growth factor IGF2, may be the most-studied M-6-P free ligands, having major 
importance in both embryogenesis and carcinogenesis. There is a clear functional link 
between these two ligands: while IGF2 does not inhibit RA binding to M6P/IGF2R, the 
RA has been shown to stimulate IGF2 internalization [13]. 
Due to the fact that IGF2 binds to IGF1 and insulin receptor, in addition to 
M6P/IGF2R, its final influence on cell functioning clearly depends on the targeted 
receptor. Its growth-promoting effects are mediated by its binding to IGF1 and/or insulin 
receptors. On the other hand, IGF2 recognition and internalization through the 
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M6P/IGF2R has proved to be a general mechanism for modulating the IGF2 circulating 
levels through lysosomal degradation. The best evidence for this mechanism of action 
comes from gene targeting studies showing a fetal overgrowth, elevated levels of 
circulating IGF2, and perinatal lethality due to major cardiac abnormalities in M6p/Igf2r 
deficient mice [17,18]. Knocking out either M6p/Igf2 or Igf1r completely rescued this 
phenotype [19]. 
In vivo, even a modest increase of M6p/Igf2r, as recently shown in M6p/Igf2r 
transgenic mice expressing high levels of Igf2, causes a significant delay in the 
occurrence of breast tumor. At the same time, it decreases their multiplicity [20]. 
However, the first evidence of M6P/IGF2R’s suppression function came far earlier, from 
in vitro studies. 
 
3. Recognizing M6P/IGF2R as a tumor suppressor gene 
 
The tumor suppressor function of M6P/IGF2R was initially proved in 1999. 
Transfection of a JEG-3 choriocarcinoma cell line with human M6P/IGF2R sense and 
antisense RNAs (nt 1-718) caused reduced M6P/IGF2R expression and a significant 
increase in cell growth rate. Both types of transfectants were injected into nude mice. As 
expected, the antisense transfectants induced significantly larger tumors in a higher 
proportion of animals as compared to sense transfectants [21]. The same type of 
experiment was performed in the opposite direction. The expression of exogenous wild-
type M6P/IGF2R in SW48 colon cancer cells, originally containing mutated M6P/IGF2R 
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in poly(G)8 region, induced a significant decrease in growth rate and an increased rate of 
apoptosis [22]. Several lines of evidence further supported these findings.  
Transfection of MCF-7 cells with a ribozyme cleaving more than 40% of 
endogene M6P/IGF2R target, reduced both -glucuronidase and the IGF2 internalization 
~40%, induced the MCF-7 cells growth and decreased the apoptotic rate upon TNF 
treatment [23]. On the other hand, transfection of full length cDNA in M6P/IGF2R non-
expressing mouse breast cancer cells 66cl4 did not decrease, surprisingly, their in vitro 
growth capacity and invasiveness. However, the ability of these cells to form tumors in 
vivo was seriously diminished as a result of their decreased growth rate [24].  
Another experimental model, based on the transfection of full-length M6P/IGF2R 
cDNA into M6P/IGF2R-deficient lung cell carcinoma cell line SCC-VII, showed similar 
results. M6P/IGF2R expression established the restoration of intracellular retention and 
the processing of lysosomal cathepsins B-, D- and L (as contrasted with their pericellular 
accumulation in non-transfectants) which negatively impacted an anchorage-independent 
proliferation and invasiveness in vitro and tumor growth in vivo [25]. All these valuable 
studies have dealt with relatively narrow aspects of M6P/IGF2R functioning. The 
obtained results strongly support M6P/IGF2R as a suppressor gene. However, there is a 
very interesting study which shows that the M6P/IGF2R functioning should be 
considered at multiple levels. In a high percentage of LNCaP and PC-3 prostate cancer, 
its forced expression resulted in an increased cell number, probably due to an increased 
proliferation rate, although one could not exclude the possibility of decreased cell 
survival. The authors suggested that the IGF2 and M-6-P binding functions have opposite 
effects in the growth of these cells. As a cumulative result of specific binding, 
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proliferative or inhibitory signaling occurs [26]. This very intriguing, logical hypothesis 
still needs to be proved in other experimental models. 
 
4. Mutations in cancer  
  
Before 1995, when the first mutations of M6P/IGF2R were published in two 
different papers, it was well known that different malignant tumors (breast, ovary, 
melanoma, lymphoma, renal carcinoma) frequently display loss of heterozygosity (LOH) 
at 6q26-27, where M6P/IGF2R resides [27-32]. In 1995, as one might have expected 
based on previous findings, the first analyses focusing on LOH and mutation analyses in 
this particular gene were published. 
 
4.1. Breast cancer 
 
In the first study, based on 40 breast cancer samples (21 invasive carcinomas, 19 
ductal carcinomas in situ (DCIS)), LOH was found in 12 samples, among them five 
carcinomas in situ. The DCIS LOH samples were further sequenced and two mutations 
were found, one in exon 31 (Gln1445His) and one in exon 40 (Thr2379Pro) [33]. In 
1997, this finding was confirmed: LOH was detected in 4 out of 18 DCIS [34]. However, 
the suggestion that LOH of the M6P/IGF2R represents an early event in breast 
carcinogenesis was not supported by recent results obtained in a large study based on 
immunohistochemistry.  
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An overall and significant overexpression was shown in the high-grade DCIS 
(N=61) as compared to normal adjacent tissues [35]. On the other hand, a significant 
decrease of M6P/IGF2R in 24% of analyzed invasive breast carcinomas (N=133) 
supported the loss of its suppressing function in advanced, invasive breast tumors [35]. 
Based on these three reports, it is clearly not easy to determine the role of M6P/IGF2R 
receptor in the early steps of carcinogenesis in breast tissue.  
Radiation alters the level of its mRNA, as shown in MCF-7, T47D (both ER-
positive) and MDA-MB-231 (ER-negative) breast cancer cell lines, after being irradiated 
with 2 Gy. The mechanism for this phenomenon seems to be stabilization of the 
M6P/IGF2R transcript. The potential therapeutic clinical implications of this observation 
need to be explored [36]. 
 
4.2. Hepatocellular cancer (HCC) 
 
In the second early study, LOH was shown in 11 of 16 informative HCC samples. 
Additional LOH was detected in one of three analyzed fibrolamellar tumors and two of 
[37]. While this last result strongly indicated that M6P/IGF2R LOH was an early event in 
liver carcinogenesis, the results of this study and several other studies also pointed out 
M6P/IGF2R dysfunction as a relatively common event in these types of tumors. This was 
not confirmed in only one study [38]. Although the authors [38] hypothesized that the 
M6P/IGF2R LOH may not be common in Japanese HCC patients, some other results 
obtained on a Japanese population do not support this hypothesis [39]. However, the 
research based on M6P/IGF2R in these specific tumors was, in fact, the extensive study 
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of M6P/IGF2R mRNA quantification in HCC. This study showed a 58% decrease of 
M6P/IGF2R mRNA and 27% of protein in 7 of 11 carcinomas, as compared with normal 
liver tissue. Hence, the mutations discovery was the result of a logical step forward [40]. 
Already in 1996, the tumors analyzed [37] were sequenced and mutations were detected 
in four tumor samples: three with proven LOH (Gly1449Val, Gly1449Glu and one 
sample with splice mutation) and two samples with retained wild-type allele 
(Gly1464Glu and one splice mutation) [41]. 
Loss of heterozygosity analysis was performed in five more studies, All together, 
these studies included 146 informative patients [37-39, 42-44]. In some cases, two or 
more separate analyses were performed on DNA extracted from different topological 
tumor sites and/or regenerative and dysplastic nodules (DS). For this reason, the number 
of heterozygous samples analyzed in these studies is bigger than the number of patients: 
168 (145 HCC). The total number of LOH positive HCC samples was 79 (79/145, 
54.5%). LOH was also present in a smaller proportion of dysplastic nodules (Table 1). 
This is a very interesting finding because dysplastic liver lesions are considered to be the 
HCC precursor.  
The samples with LOH were further analyzed for the presence of mutations in 
three of these studies [38, 39, 43]. In Yamada’s study, the amplified exons 27-28 (AAs 
1224-1339) and 31 (AAs 1418-1481) were directly sequenced [43]. The targeting was 
well designed to explore the possibility of existence of M6P/IGF2R hot spots existence, 
because mutations in amino acids 1445, 1464 and 1449 were already known [33,41]. 
Mutations were present in six of 11 LOH positive tumors. These included the already 
known Gly1449Val in two samples, a new mutation Cys1262Ser in another sample and 
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frameshift mutations induced by „G“ deletion in poly(G)8 repeat present in exon 28 
(NM_000876: nucleotides 4089-4096) in three additional samples. This specific mutation 
will be discussed later. 
In the second paper, mutations were present in 9 of 43 HCC LOH -ositive tumors, 
but not in the LOH-positive (3/4) DS [39]. In addition, dissected, phenotypically 
unchanged liver tissue adjacent to HCC showed LOH in two out of five samples. The 
analyzed region was far broader than in previous research as it included sequencing of 
exons 8-10 (AAs 295-438), 27-35 (AAs 1224-1722) and 37-40 (AAs 1773-2022). Hence, 
it was not surprising that the spectrum of discovered mutations broadened: Asp1268Asn, 
Met1625Leu, Pro1444Ser, Ser1628Phe, Gly1315Gln, His1878Gln, Thr1650Ile and an 
already known mutation consisting of „G“ deletion in the poly(G)8 repeat stretch of exon 
28. In order to understand the meaning of these mutations, one should be familiar with 
the specific functions of the receptor, relating to its „molecular anatomy“. The amino 
acids 1445, 1449 and 1464 belong to repeat 10 (AAs 1395-1532) (Figure 1). Contrary to 
expectations, this repeat is not the binding repeat domain for IGF2, nor it is considered 
the key repeat for M-6-P binding (Figure 1).  
 
4.3. Other types of cancer 
 
Prostate cancer loss of M6P/IGF2R mimics the HCC: among 36 informative 
patients, LOH was present only in malignant tumor tissues of 15 patients. It was also 
detected in high-grade PIN (prostatic intraepithelial neoplasia) which was present in 7 of 
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11 of these patients. This may indicate that LOH of M6P/IGF2R represents an early 
genetic event in prostate cancer [45].  
It is surprising that there is only one mutational research study on M6P/IGF2R in 
lung cancer performed on paraffin-embedded sections [46]. It included 22 patients, all 
were smokers. Both LOH and mutational analyses were done through DNA sequencing. 
Among 19 heterozygous persons, LOH was present in 11 (11/19). On further sequencing 
(exons 8-11, 27-29, 31, 33-34, 37-39) of these 11 samples, six mutations were 
discovered, as shown in Table 1. Based on this study, it was not possible to estimate the 
importance of M6P/IGF2R in early lung carcinogenesis. However, we have noticed that 
two mutations considered to be substitution point mutations resulting in Gly1296Arg and 
Gly1564Arg substitutions, may, in fact, be splice-site mutations. In the first case, the 
coding triplet of nucleotides for glycine, GGT, changes into CGT. In the second case the 
glycine coding triplet GGG changes into CGG. In both cases, the codin triplets originate 
from two different exons. In both cases, the first coding nucleotide originates from the 5’ 
(upstream) exon (27 and 33, respectively), while the remaining two nucleotides originate 
from the 3’ (downstream) exons (28 and 34, respectively). We have analyzed these two 
mutations through the Human Splicing Finder and the program calculated the variation to 
be >10% [47]. Based on these results, we conclude, with confidence, that these two 
mutations affect the donor splice side. As a consequence, one would expect exon-
skipping with unstable RNA/protein or the activation of a cryptic splice site leading to 
premature termination codon and non-sense-mediated mRNA decay. If this really 
happened, then it may be an additional explanation for the lack of M6P/IGF2R protein in 
the samples with these two mutations.  
13 
 
In vitro analysis performed on 22 different cancer cell lines that were resistant to 
growth inhibition by TGF- , showed an aberrantly migrating band obtained by 
amplification of exon 40, originating from DNA extracted from lung adenocarcinoma cell 
line NMS-Lu3. It was further sequenced. Point mutation resulting in asparagine to serine 
substitution was detected at codon 2020 (Figure 1) [48].  
In a subset of 25 laryngeal squamous cell carcinomas (all patients were smokers), 
LOH was found in only three samples. All of them were in an advanced stage and of high 
grade, strongly indicating LOH of M6P/IGF2R as a late event in laryngeal carcinogenesis 
[49]. This is in accord with findings obtained on adrenocortical tumors, where LOH was 
detected in 15 tumors, among them 11 were malignant. It did not, however, correlate with 
tumor expansion or metastatic potential [50]. The results of LOH analyses from several 
other studies are shown in Table 1 [51-55]. We have tried to collect and present all 
relevant data, but there is a possibility that we may have missed some. 
 
4.4. Microsatellite instability and M6P/IGF2R mutations, the importance of 
specific polymorphisms 
 
Genetic mutational studies had profiled a repetitive stretch of 8 “G” (poly(G)8) 
nucleotides in coding region of M6P/IGF2R (exon 28) as a locus minoris resistentiae. 
These were always joined with tumors which demonstrate microsatellite instability (MI). 
The consequence of one or two base pairs insertion/deletion is the creation of premature 
stop codon. Although not considered as a Real Common Target for mutation occurrence 
in three different cancer types (colon, endometrium stomach), based on statistical meta-
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analysis proposed by Woerner et al. (which was criticized later), the reported rate of 
mutation in this specific area is quite high, especially in colorectal tumors (10-28%), as 
shown in Table 2 [56, 57]. The importance of these specific mutations in this region has 
been well recognized and some recent studies focus on this region.  
Unfortunately, due to the lack of stringent and well-described criteria that would 
define the MI status of the 148 sporadic breast cancer tumors in which mutation in this 
region was not found (based on results obtained in other tumor types one would expect 
that all, or most of these tumors were MI negative), it is not possible to include this study 
in the statistics of specific mutations for the purpose of this review [58]. However, the 
same study showed one “G” deletion in breast cancer cell lines CAL51 and MT-31 [58]. 
Based on available data, it seems that some 15% of MI positive tumors have mutation in 
poly(G)8, which is quite high (Table 2) [59-64]. 
In addition, there is a stretch of variable number of „GT“ repeats at the 3' prime of 
the gene (NG_011785, nt:141809-141840). According to two reports, this variability may 
relate to the increased susceptibility to both lung cancer and oral squamous cell 
carcinoma [65, 66]. It would not be surprising if a different number of „GT“ repeats in 
3'UTR changed the list of mi-RNA binding candidates, making them potential regulators 
of M6P/IGF2R activity. However, this hypothesis needs to be confirmed through strong 
experimental data. Our preliminary search of this region through several micro-RNA 
databases did not show any mi-RNA that would target the M6P/IGF2R mRNA in the area 
of these specific repeats [67].  
Finally, some recent data indicates the importance of certain polymorphisms in 
M6P/IGF2R (rs998075, rs998074) as possible risk factors for osteosarcoma. It was 
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proposed that aberration of CpG methylation due to the presence of polymorphism 
induces changes in gene expression. However, this was not supported with functional 
data obtained at the bench [68]. On the other hand, through a comprehensive analysis 
(site-directed mutagenesis, qRT-PCR, cell cycle analysis, NMR spectroscopy) that also 
included bioinformatics, it was shown that the M6P/IGF2R polymorphism Gly1619Arg 
in repeating domain 11 has no effect on its structure, real-time ligand binding kinetics, 
protein half-life and its cellular distribution [69]. More multilevel research will be needed 
in order to understand the functional consequences of the M6P/IGF2R polymorphisms 
discovered so far. The same applies to mechanisms which regulate its activity. 
 
5. Epigenetic regulation of M6P/IGF2R transcription 
 
Some recent data points out very interesting epigenetic mechanisms that influence 
the M6P/IGF2R transcription. In mice, the gene is crucial for survival. Knock-out Igf2r 
mice were dying in utero around the time of birth [17]. Contrary to primates, including 
humans, where M6P/IGF2R expression follows biallelic mode of expression, the gene is 
maternally expressed (paternally imprinted) in rodents, marsupials and artiodactyls [70]. 
However, in a subset of individuals, human M6P/IGF2R expression can be 
predominantly or exclusively transcribed from the maternal allele [71]. 
In mice, the Igf2r gene codes two reciprocally - imprinted transcripts, due to two 
differentially-methylated, cytosine rich, regions (DMRs). While the first one (DMR1), 
includes promoter for maternally expressed sense Igf2r transcript, the second one 
(DMR2), positioned in the second intron of the Igf2r, includes promoter for paternally 
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expressed antisense transcript, Air [72]. Contrary to mice, human M6P/IGF2R contains 
only one DMR positioned in intron 2, and there are no antisense transcripts [73]. In 
addition to this CpG island, there are two more islands in humans: one located in its 
promoter region (usually unmethylated) and the other located in intron 44. 
The mechanism of biallelic expression of M6P/IGF2R in a majority of humans 
was a subject of controversy in light of a well-known fact on the broad deviation of DMR 
methylation status [74]. It was estimated (based on a study that included 680 individuals), 
that 11% and 3% of people have an abnormally low or high level of DMR methylation on 
the paternal allele, respectively [75]. On the other hand, the data obtained from histone 
modifications analyses was consistent, as there is an equal enrichment of active histone 
modifications (acetylation of H3 and H4 and di- and tri-methylation of H3-Lys4 and H3-
Lys9) in the promoter region on both parental alleles. In mice, on the other hand, there is 
a clear difference in histone modifications relating to a specific allele. Activating 
modifications were found only at the M6p/Igf2r promoter on the maternal allele, while 
the same enrichment on the paternal allele was localized only in the Air promoter region 
[76]. 
 
6. Mutation versus protein function 
 
Intermolecular cross-linking of two M6P/IGF2R was originally shown on the 
binding of multivalent ligand, -glucuronidase [77]. The mechanism of this interaction 
came from two more studies: the first one showed that dimerization occurs independently 
of ligand binding, while the results of the second study clearly showed that there is no 
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specific dimerization domain. Hence, oligomerization seems to be a result of multiple 
interactions that exist along the ectodomain of the receptor [78, 79]. The last data show 
that IGF2 binds independently to repeating domain 11 on each receptor monomer. On the 
other hand, M-6-P bearing ligand binding is bivalent, and this kind of binding requires 
cooperative interaction of cognate sites on both monomers of the dimeric receptor. 
In humans, two IGF2 hydrophobic binding sites are located in repeating domain 
11 (AAs 1533-1666) contributed by the residues in repeating domain 13 (AAs 1821 – 
2008) and necessary for high affinity IGF2 binding (10
-10
 mol/L) [80, 81]. Site-directed 
studies have revealed IGF2 amino acids F48, R49, S50, A54 and L55 as critical for IGF2 
binding to M6P/IGF2R. It was also shown that surface-exposed residues, not directly 
involved in binding itself, strongly influence the binding affinity [82]. In M6P/IGF2R, 
the residues Y1542, S1543, G1546, F1567, G1568, T1570, I1572, S1596, P1597 and 
P1599 have been considered as “the candidates“ involved in this interaction [83]. 
Another study confirmed the crucial binding role for I1572 (profiled as crucial for this 
interaction already in 1999), and for F1567. These two amino acids seem to be strong 
candidates for anchoring interactions with F48 and L55 [84, 85]. Among in vivo 
occurring mutations that were studied in these models, three mutations were discovered 
in lung carcinoma (Gly1564Arg – discussed previously regarding the possibility of 
misinterpretation: point mutation vs. splice mutation, Ala1618Thr, Gly1619Arg) and they 
directly affect repeating domain 11. According to Brown, Gly1564Arg probably disrupts 
the secondary structure of the protein, while the effects of the other two mutations seem 
to be small [83]. 
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In the model proposed in 2002, even-numbered domains face one direction, while 
the odd-numbered domains face the opposite direction. According to this model, the 
putative IGF2 repeating domain 11 is adjacent to repeating domain 13 which contains 
fibronectin type II-like insert [83]. 
On the other hand, there are three binding sites for M-6-P containing ligands. Two 
high affinity binding sites are localized in domains 1-3 (crystallography reveals that 
repeat 3 sits on the top of repeats 1 and 2), and 7-9. One low affinity site maps to domain 
5 [84, 85]. The difference in binding capacity is possibly due to the absence of two 
cysteine residues which form a stabilizing disulfide bond in repeats 3 and 9 [86]. Site-
directed mutagenesis studies have identified the core binding site residues in repeating 
domains 3 and 9 to be made of a glutamine, a glutamate, a tyrosine and an arginine 
residues [87, 88]. Finally, Olson's crystallographic study revealed that the receptor forms 
five three-repeat units with binding sites for IGF2 and M-6-P stand on the opposite face 
of the receptor [89]. 
Because most of mutations occur in the extracytoplasmic domain, it was very 
important to understand how these mutations alter the function of the protein. 
 
6.1. Significance of specific mutations 
 
The first functional analyses of the mutant M6P/IGF2R, published in 1999, were 
based on a mini receptor mutation construct. Mutant full-length M6P/IGF2R cDNAs 
were transfected into 293T cells and expressed as soluble receptor constructs [90, 91]. 
The specific five mutations tested in this system were: Gln1445His, Gly1449Val, 
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Gly1464Glu, Ile1572Thr, Cys1262Ser. Among all these amino acids, only the glycine at 
1464. is not conserved in humans, rats, bovines and mice, while all other amino acids are. 
That fact itself indicates their importance in the M6P/IGF2R functioning.  
These experiments revealed the importance of 1572. isoleucine. Its substitution 
with threonine completely abolishes the IGF2 binding. The mutants Cys1262Ser and 
Gly1449Val demonstrated a measurable reduction in ligand-receptor association (60% 
decrease). Glu1445His and non-conserved Gly1464Glu bound it with almost wild-type 
affinity. Regarding the underlying mechanism for reduced binding of both IGF2 and M-
6-P by mutants Cys1262Ser and Gly1449Val, it was a surprising discovery that these two 
mutations decrease the number of binding sites, although both mutants are eventually 
capable of interacting with ligands. Several explanations were offered and all of them are 
based on a change in M6P/IGF2R conformation as a consequence of mutation. 
 
7. Directly involved in cell signaling? 
 
Finally, although its cytoplasmatic tail lacks a kinase domain, there are a number 
of older studies providing evidence for a signaling role as well as for interaction with 
heteromeric G-proteins [92-94]. It still needs to be discovered how the physiological 
concentrations of soluble M6P/IGF2R inhibits DNA synthesis in both hepatoma cells 
(BRL cells) and mice fibroblasts (3T3 cells). The same paper showed that the inhibitory 
effect on DNA synthesis can be reduced by the presence of IGF2 [95]. A similar effect 
was obtained with MDA-MB-231 cells stably transfected with full length M6P/IGF2R 
cDNA. In addition to decreased DNA synthesis, the tumor-forming capacity of these cells 
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was significantly diminished, as shown in vivo on athymic nu/nu mice. Finally, there was 
a 50% decreased level of IGF1-R phosphorylation, accompanied by reduced 
phosphorylation of ERK1/ERK2 in these cells [96]. Due to the fact that an increase in 
M6P/IGF2R decreases the bioavailability of IGF2, the silencing of IGF1R signaling 
pathway can be considered a logical consequence.  
However, the latest published study relating to the possible signaling function of 
M6P/IGF2R, gave somewhat opposite results: in vitro siRNA down-regulation of 
M6P/IGF2R leads to a significant reduction in IGF2 (and not IGF1)-stimulated, 
heterotrimeric G-protein dependent, ERK1/ERK2 activation. This is in accord with the 
hypothesis that direct signaling through M6P/IGF2R receptor may exist [97]. The 
meaning of these opposite recent discoveries needs to be explored further. There may be 
a possibility that the difference obtained in these experiments reflects the genetic 
background of the cell models taken for these experiments (MDA-MB-231- invasive 
breast cancer cell lines vs. HEK293 - human embryonic kidney cell line). Also, the 
different methods that were used in these studies, cannot be entirely excluded as the 
reason for the obtained differences. 
 
8. Conclusion 
 
More than 10 years ago, it was proposed that there was a multifunctional 
involvement of M6P/IGF2R in cancer, starting with its role as a mediator of protease 
activity, its importance for TGF-  activation and an increase in IGF2 degradation [98]. 
Today, keeping in mind the importance of its extensive arrays of ligands, it is hard to 
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imagine the process related to carcinogenesis not including its role. Logically, and in the 
detail discussed in a recent review, there are many potential therapeutic applications 
relating to M6P/IGF2R [99]. So far, the most promising results are obtained with 
synthesized M6P analogues which may change the binding affinity of M6P/IGF2R. 
Hopefully, the development of potential drugs which will influence M6P/IGF2R activity 
and/or function in cancer, will become a reality. This will not be an easy task, primarily 
due to the selectivity needed. To succeed in targeting the IGF2 binding site without 
affecting the rest of receptor’s activities would be an important and encouraging step 
forward. 
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Figure 1. M6P/IGF2R: coding region and corresponding protein sequence 
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Fig. 1. M6P/IGF2R: coding region and corresponding protein sequence. The letters correspond to amino acids. Italic and underlined: amino acids coded by two 
exons (numbers of coding exons are given above them). Bold and enlarged letters: positions of mutations (according to the text and Table 1). 
Table 1. M6P/IGF2R mutations in human clinical samples 
 
 Total number of samples (patients)/informative number of 
samples/patients/LOH 
 Mutation Analyses 
Reference Samples 
with 
mutation 
Analyzed 
exons 
Mutation found 
(mutation 
frequency) 
Mutation 
position 
BREAST 
62/40/12 
Informative samples: 21 invasive, 19 in situ 
LOH: 7 invasive and 5 ductal in situ (DCIS) 
 
2/5 31, 48 
Gln1445His (1) 
Pro2379Thr (1) 
Exon 31 
Exon 48 
[33] 
62/43/4 
Informative samples: 25 early invasive, 18 DCIS 
LOH: 4 DCIS 
 
NOT DONE [34] 
LIVER 
37(27)/26(18)/16(13) 
informative samples: 18 HCC, 8 dysplastic lesions (DL) 
LOH: 11 HCC, 5DL; only HCC samples were further sequenced 
 
6/11 27-28, 31 
poly(G)8, delG (3) 
Cys1262Ser (1)* 
Gly1449Val (2) 
Exon 28 
Exon 27 
Exon 31 
[43] 
36/22/14 
Informative samples: 16 HCC, 3 fibrolamellar tumors, 3 
adenomas 
LOH: 11 HCC, 2 adenomas, 1 fibrolamellar tumor 
 5/ 11 
Whole 
cDNA 
Tyr2024Stop (splice 
site mutation) (2) 
Gly1449Val (2) 
Gly1464Glu (1) 
Intron 40 
 
Exon 31 
Exon 31 
[37,41] 
30/22/11  NOT DONE [42] 
129 (93)/68(54)/46 
Informative samples: 64HCC, 4DLs 
LOH: 43 HCC, 3DLs 
 9/46 
8-10, 27-
35, 37-40 
 
Asp1268Asn (1) 
Met1625Leu (1) 
Pro1444Ser (1) 
Ser1628Phe (1) 
Gly1315Gln (1) 
His1878Gln (1) 
Thr1650Ile (1) 
poly(G)8, insG (2) 
Exon 27 
Exon 34 
Exon 31 
Exon 34 
Exon 28 
Exon 38 
Exon 35 
Exon 28 
[39] 
41/3/2  NOT DONE [44] 
48(42)/27/1 
Informative samples:22 HCC, 2 adenomatous hyperplasia, 3 
regenerative nodules 
LOH: 1 HCC 
 0/48 27, 28, 31 NOT DETECTED [38] 
PROSTATE 
43/36/15 
PIN in 11 out of 15 samples with LOH in tumor. 
LOH in PIN 7/11 
 NOT DONE [45] 
Bold underlined: LOH samples that were further sequenced; Bold#: possible splice-site mutation 
 
HEAD AND 
NECK 
87/56/30 
Informative samples: 17 base of tongue, 11 tonsil, 12 larynx, 9 
hypopharynx , 2 paranasal sinuses, 5 oral cavity 
LOH: 7 base of tongue, 7 tonsil, 9 larynx, 3 hypopharynx, 4 oral 
cavity 
 NOT DONE [52] 
LARYNX 35/25/3  NOT DONE [49] 
LUNG 22/19/11  6/11 
8-11, 27-29, 
31, 33-34, 
37-39 
Gly1296Arg (1)# 
poly(G)8, insG (1) 
Gly1564Arg (1)# 
Ala1618Thr (1) 
Gly1619Arg (2) 
Exon 27 
Exon 28 
Exon 34 
Exon 34 
Exon 34 
[46] 
OVARIUM 
4/4/3  NOT DONE  [54] 
8/8/6  0/6 
whole 
M6P/IGF2R 
cDNA 
NOT DETECTED [51] 
ADRENAL 
GLAND 
76/57/15 
Informative adrenocortical tumors: 22 benign, 16 suspect, 
19 malignant 
LOH: 2 benign, 2 suspect, 11 malignant 
 NOT DONE [50] 
ENDOMETRIUM 46/32/16  8/16 
27, 28, 33, 
34 
poly(G)8, insG (2) 
The rest of mutations 
not specified. 
Exon 28 
[53] 
Bold underlined: LOH samples that were further sequenced; bold#: possible splice-site mutation. 
 
* mentioned inRref. [55] as “unpublished data” 
 
Table 1. M6P/IGF2R mutations in malignant tumors with microsatellite instability (MI) 
 
Clinical cancer 
samples 
Total number 
of samples 
MI-
negative 
MI-
positive 
PolyG(8) mutation 
presence 
References 
Breast 20 20 0 0 [60] 
Endometrium 100 74 26 4 [60] 
Ovarium 39 39 0 0 [60] 
Esophagus 1 0 1 0 [59] 
Pancreas 
51 
2 
44 
0 
7 
2 
0 
0 
[60] 
[59] 
Stomach 
81 
29 
69 
0 
12 
29 
3 
7 
[60] 
[59] 
Colorectum 
114 
342 
51 
90 
92 
96 
279 
0 
0 
0 
18 
63 
51 
90 
92 
1 
14 
5 
23 
9 
[60] 
[61] 
[59] 
[62] 
[63] 
Total number of 
samples 
1012 621 391 66 
 
Mutation 
presence 
 0/528 
66/391 
(16.8%) 
 Mutations were 
present only in MI-
positive tumor samples 
Cancer cell lines 
and 
xenographts 
Total number 
of samples 
    
Breast 
11 
(cell lines) 
9 2 
2 
(MI-positive CAL-51 and 
MT-3) 
[58] 
Prostate 
28 
(6 cell lines, 
22 xenografts) 
22 6 
2 (MI-positive xenograft 
LAPC4 and MI-negative 
xenograft PC82) 
[64] 
 
 
 
 
 
